Zentiva S A : Zent2U announces successful development completion of Metformin with controlled NDMA content

Zent2U's development of innovative manufacturing processes to control impurities, including N-nitrosodimethylamine (NDMA), is completed and the opportunity is now offered to you. Zentiva's improved processes have been successfully implemented into industrial use and Zentiva has related intellectual property rights. Application concerning worldwide patent rights is pending.

Solving this complex task, which is closely observed by global regulators, allows Zentiva to offer complete EU dossiers to partners. We believe that having a Metformin finished drug product with controlled nitrosamine impurity content will bring significant advantages to millions of diabetes patients. Further, this innovation will advantage our potential business partners in overcoming nitrosamine impurity issues and allow the launch of the improved product quickly, with critical NMDA reduction and benefiting from Zentiva's proprietary technology.

Contact:

Tomas Pilarcik

Key Account Manager

E: [e-mail]

(C) 2021 Electronic News Publishing, source ENP Newswire